NEUROPHET Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	2,590	2,615	2,216
Revenue Growth	-	18.00%	-
Cost of Revenue	5.94	3.91	1.27
Gross Profit	2,584	2,611	2,215
Selling, General & Admin	13,861	12,337	9,739
Research & Development	6,665	5,276	5,987
Amortization of Goodwill & Intangibles	145.04	148.53	141.42
Other Operating Expenses	125.39	108.99	62.28
Operating Expenses	22,218	19,160	16,864
Operating Income	-19,634	-16,549	-14,649
Interest Expense	-552.65	-920.64	-3,614
Interest & Investment Income	740.97	413.26	468.72
Currency Exchange Gain (Loss)	23.02	-9.89	-17.5
Other Non Operating Income (Expenses)	-4,197	-5,323	2,713
EBT Excluding Unusual Items	-23,620	-22,389	-15,098
Gain (Loss) on Sale of Assets	-0.28	-0.08	-3.48
Pretax Income	-23,620	-22,389	-15,101
Net Income	-23,024	-22,389	-15,101
Net Income to Common	-23,103	-22,389	-15,101
Net Income Growth	-	-	-
Shares Outstanding (Basic)	12	10	4
Shares Outstanding (Diluted)	12	10	4
Shares Change	-	163.51%	-
EPS (Basic)	-1969.42	-2301.74	-4091.00
EPS (Diluted)	-1969.42	-2301.74	-4091.00
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-18,244	-15,332	-12,862
Free Cash Flow Per Share	-1555.22	-1576.25	-3484.24
Gross Margin	99.77%	99.85%	99.94%
Operating Margin	-758.18%	-632.84%	-660.98%
Profit Margin	-892.16%	-856.15%	-681.41%
Free Cash Flow Margin	-704.52%	-586.30%	-580.35%
EBITDA	-18,488	-15,439	-13,554
D&A For EBITDA	1,146	1,110	1,095
EBIT	-19,634	-16,549	-14,649
Advertising Expenses	-	799.23	919.06